AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12163777
Drug: Normal values
RxNorm normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal values as goals or therapy that did not improve oxygen delivery
Trial: 9797239
Drug: 1% cidofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% cidofovir gel
Trial: 9797239
Drug: 3% cidofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% cidofovir gel
Trial: 9797239
Drug: 5% cidofovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% cidofovir gel
Trial: 7705123
Drug: Mesna (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesna (3 mL)
Trial: 7705123
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (3 mL)
Trial: 2768152
Drug: Methylphenidate (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (highest dose)
Trial: 2768152
Drug: Methylphenidate (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (lower dose)
Trial: 861124
Drug: Nitrazepam 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrazepam 2.5 mg
Trial: 27613951
Drug: Combustible Cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combustible Cigarettes (CC)
Trial: 23541711
Drug: 3.5 mg
RxNorm normalized name: niacin 13.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mg Zolpidem Sublingual Tablet (ZST)
Trial: 23541711
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Immediate-Release (IR) Oral Zolpidem
Trial: 19074594
Drug: Candesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (angiotensin II type 1 receptor antagonist)
Trial: 15119520
Drug: Outpatient strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Trial: 15119520
Drug: Inpatient strategy
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Trial: 10665615
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate 600 mg/wk
Trial: 7984574
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies OKT-4 and OKT-8 used in tuberculous patients
Trial: 30571562
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of angiotensin-converting enzyme inhibitor-based therapy
Trial: 25251676
Drug: ADF-L (lunch)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADF-L (lunch)
Trial: 21164045
Drug: Curcumin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin group (10 participants) ingested 8 g of curcuminoids (C(3)‐Complex) with 16 oz of bottled water.
Trial: 18066139
Drug: Protein-source tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protein-source tryptophan (deoiled gourd seed) in combination with carbohydrate
Trial: 11295690
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (low-dose warfarin sodium and aspirin)
Trial: 27064030
Drug: Drospirenone (DRP)‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (DRP)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Trial: 27064030
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Trial: 24637997
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with chemotherapy (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks)
Trial: 20521348
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (four cycles of carboplatin and paclitaxel)
Trial: 17517949
Drug: pyrimethamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrimethamine (50 mg/day) plus sulfadiazine (4 g/day) and folinic acid (25 mg/day)
Trial: 17517949
Drug: trimethoprim (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim (10 mg/kg/day) plus sulfamethoxazole (50 mg/kg/day) (TMP‐SMX)
Trial: 12792513
Drug: Vitamin supplementation
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin supplementation (folic acid 5 mg/day; vitamin B(6) 50 mg/day; vitamin B(12) 400 microg)
Trial: 10676599
Drug: Intravenous Optison®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Optison® (FS069) at 0.5 ml
Trial: 10676599
Drug: Intravenous Optison®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Optison® (FS069) at higher doses (0.2, 3.0, and 5.0 ml)
Trial: 8800113
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of high dose furosemide (mean daily dosage 690 mg, range 250 to 2,000)
Trial: 8800113
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of high dose furosemide (equal dosage to infusion)
Trial: 8800113
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of high dose furosemide
Trial: 8800113
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of high dose furosemide
Trial: 1624171
Drug: High glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High glycine amino acid solution (23% glycine nitrogen)
Trial: 1624171
Drug: Low glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low glycine amino acid solution (4% glycine nitrogen)
Trial: 1624171
Drug: High glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High glycine amino acid solution (25% glycine nitrogen)
Trial: 1624171
Drug: Low glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low glycine amino acid solution (8% glycine nitrogen)
Trial: 30654297
Drug: pembrolizumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab + CC-486
Trial: 19158225
Drug: DHA oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA oil (7.5 g/d, 3 g DHA/d)
Trial: 12607378
Drug: Web based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web based IT solutions for studies and registers
Trial: 12607378
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of web based IT solutions
Trial: 10979879
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (200 mg/wk)
Trial: 10979879
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (three times weekly)
Trial: 8780431
Drug: Inositol (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inositol (18 g/day)
Trial: 1467134
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BAY u 3405
Trial: 1467134
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BAY u 3405
Trial: 27814306
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy for 30 minutes followed by treadmill training only for 30 minutes
Trial: 17453688
Drug: Goserelin 3.6
RxNorm normalized name: goserelin 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin 3.6 mg
Trial: 17453688
Drug: Leuprolide 3.75
RxNorm normalized name: leuprolide 3.75 mg intramuscular powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide 3.75 mg
Trial: 18685605
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea infusion
Trial: 10787075
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (low dose intravenous epirubicin 20 mg/m2 and mitomycin 5 mg monthly for seven courses starting 5 to 6 weeks after surgery)
Trial: 8857631
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (i.v.)
Trial: 30299473
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (simvastatin)
Trial: 29730268
Drug: Bilateral thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral thoracic paravertebral block at T8 with an infusion of 0.2% ropivacaine
Trial: 29730268
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia at T7/8 with an infusion of 0.125% bupivacaine with hydromorphone 6 μg/mL
Trial: 26583966
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume training (2 sets of 5 repetitions, twice a week)
Trial: 26583966
Drug: Moderate volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate volume training (4 sets of 5 repetitions, twice a week)
Trial: 18366642
Drug: Hypertension (BP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension (BP > or = 140/90 mmHg and/or treatment)
Trial: 18366642
Drug: Diabetes (fasting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes (fasting plasma glucose > or = 7 mmol/l and/or treatment)
Trial: 9592303
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 1 week
Trial: 9592303
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 2 weeks
Trial: 9592303
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate 240 mg twice daily, amoxicillin 1,000 mg twice daily, metronidazole 400 mg twice daily for 2 weeks
Trial: 1872348
Drug: Multiple choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple choice response format (oral and written)
Trial: 1872348
Drug: Usual history
RxNorm normalized name: histolyn CYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual history question (oral and written)
Trial: 31771375
Drug: Controller medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controller medication use (≥8 days over 2 weeks)
Trial: 31487819
Drug: Native whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native whey (20 g, 2 servings daily)
Trial: 31487819
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein (20 g, 2 servings daily)
Trial: 8118992
Drug: Plasma spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma spray cementless THR (Mallory‐Head)
Trial: 2563606
Drug: Acitretin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (40 mg daily for 4 weeks, then individually adjusted for 8 weeks)
Trial: 2563606
Drug: Etretinate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate (40 mg daily for 4 weeks, then individually adjusted for 8 weeks)
Trial: 1100535
Drug: Demetrin 3
RxNorm normalized name: Kevetrin
DrugBank: 4-isothioureidobutyronitrile (DB13010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demetrin 3 x 10 mg/day
Trial: 1100535
Drug: Demetrin 3
RxNorm normalized name: Kevetrin
DrugBank: 4-isothioureidobutyronitrile (DB13010)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demetrin 3 x 20 mg/day
Trial: 26702086
Drug: Statewide public
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statewide public and health professional awareness campaign to increase regular aspirin use
Trial: 21521834
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg daily) administered concomitantly (CONC)
Trial: 21521834
Drug: Pantoprazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (80 mg daily) administered staggered by 8 to 12 hours (STAG)
Trial: 8951937
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tolperisone hydrochloride
Trial: 12935797
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg pridinol mesilate
Trial: 8603261
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment (n=16)
Trial: 8603261
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment in patients with HIV‐1 and tuberculosis infections
Trial: 8603261
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=16)
Trial: 8603261
Drug: Thalidomide treatment
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide treatment in patients with HIV‐1 infection only
Trial: 1584941
Drug: Amebicidal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amebicidal therapy coupled with image-guided percutaneous therapeutic aspiration
Trial: 1584941
Drug: Amebicidal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amebicidal therapy alone
Trial: 27506585
Drug: Acetaminophen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500 mg/8 h) over 6 weeks
Trial: 27506585
Drug: Intra-articular leukocyte-poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular leukocyte-poor PRP (LP-PRP) injections (three injections, once every 2 weeks)
Trial: 18591575
Drug: Dextroamphetamine (d-amph)
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (d-amph) 10 mg single dose
Trial: 12060506
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg single dose of itraconazole
Trial: 12060506
Drug: 7-day 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day 200 mg daily dose of itraconazole
Trial: 10221945
Drug: Counselling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling and emotional support (combined with active drug)
Trial: 10221945
Drug: Counselling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling and emotional support (simple psychological treatment)
Trial: 7884414
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (4 cycles of chemotherapy for 3 months before surgery followed by 4 cycles after surgery)
Trial: 7884414
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (8 cycles of chemotherapy over 6 months after surgery)
Trial: 375459
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus anticoagulants
Trial: 27373329
Drug: Bet v
RxNorm normalized name: immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bet v 1 COPs 50 μg
Trial: 27373329
Drug: Bet v
RxNorm normalized name: immunoglobulin G4-kappa, anti-[Bet v 1 (Betula alleghaniensis (yellow birch) pollen allergen 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bet v 1 COPs 100 μg
Trial: 17653314
Drug: Singulair 4
RxNorm normalized name: Singulair 4mg Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singulair 4 mg once daily for 12 weeks
Trial: 17653314
Drug: Budesonide aerosol
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide aerosol 200 ug once or twice daily for 12 weeks
Trial: 10069193
Drug: Amlodipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5 mg, once daily for 8 weeks)
Trial: 1663226
Drug: Morphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.3 mg/kg bodyweight)
Trial: 7128670
Drug: Terbutaline 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.125 mg and 0.250 mg via pressurized aerosol with pear-shaped spacer
Trial: 7128670
Drug: Terbutaline 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 1.25 mg and 2.50 mg via nebulized solution
Trial: 7128670
Drug: Initial placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial placebo treatment for both groups
Trial: 31274152
Drug: Electrically guided
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electrically guided LV lead placement with post-implant VVd optimization
Trial: 29049868
Drug: Intense intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense intervention group (home-based assessments at 6-month intervals and a 12-month multidisciplinary program with weekly group sessions)
Trial: 24397584
Drug: saxagliptin +
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saxagliptin + metformin
Trial: 24397584
Drug: glipizide +
RxNorm normalized name: Glipizide
DrugBank: Glipizide (DB01067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glipizide + metformin
Trial: 22809843
Drug: Aspirin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistance defined by response to arachidonic acid after 3, 5 and 7 minutes (approximately 30% of patients)
Trial: 22809843
Drug: Aspirin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistance defined by response to adenosine diphosphate after 3 minutes (approximately 17% of patients)
Trial: 22809843
Drug: Aspirin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistance (49 patients)
Trial: 22809843
Drug: Aspirin resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin resistance in patients with greatest renal disease
Trial: 20186975
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day + Depression Care Management (DCM) + Interpersonal Psychotherapy (IPT) for 16 weekly sessions
Trial: 20186975
Drug: Escitalopram 20
RxNorm normalized name: escitalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram 20 mg/day + Depression Care Management (DCM) without IPT
Trial: 16253070
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of norfloxacin
Trial: 12693324
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with Praziquantel (25-50 mg/kg for 14 days)
Trial: 7588990
Drug: Intranasal Apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Apomorphine
Trial: 7588990
Drug: Subcutaneous Apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Apomorphine
Trial: 6958479
Drug: 4 divided
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 divided doses of BDP
Trial: 6958479
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of BDP
Trial: 21548919
Drug: Family-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based cognitive behavioral multidisciplinary lifestyle treatment
Trial: 16682575
Drug: Electronic medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medical record alerts for coprescription of warfarin and interacting medications (acetaminophen, nonsteroidal anti‐inflammatory medications, fluconazole, metronidazole, sulfamethoxazole)
Trial: 15173406
Drug: Psychosocial intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial intervention (weekly home visits from birth to 8 weeks and from 7 to 24 months)
Trial: 8737627
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (0.125 mg and 0.250 mg brotizolam)